Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Vasculitis

• An Exploratory Study of MT-2990 in Patients With AAV
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
• A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
• The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
• ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
• PR3-AAV Resilient Remission or PRRR
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis
• Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
• Isatuximab in Type I Cryoglobulinemia
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
• Effect of Tofacitinib in Treating ANCA-associated Vasculitis
• Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
• Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
• Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated
• Hydroxychloroquine in ANCA Vasculitis Evaluation
• Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
• Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis
• Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
• Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
• Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
• The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
• Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
• Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
• Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
• Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
• Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
• Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
• A Randomized Multicenter Study for Isolated Skin Vasculitis
• Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
• Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
• Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
• Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
• Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
• Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
• Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
• The Clinical Efficacy of DFPP in Patients With AAGN
• Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
• Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
• Low-dose Glucocorticoid Vasculitis Induction Study
• Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
• Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
• Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
• Endothelin Antagonism in ANCA Vasculitis
• The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
• Phase Ib Study of SC Milatuzumab in SLE
• Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
• Rituximab Vasculitis Maintenance Study
• Belimumab in Remission of VASculitis
• CMV Modulation of the Immune System in ANCA-associated Vasculitis
• BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
• Plasma Exchange for Renal Vasculitis
• Alemtuzumab for ANCA Associated Refractory Vasculitis
• A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
• Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
• Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
• GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
• Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
• Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
• Anti-Cytokine Therapy for Vasculitis
• Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
• Efficacy Study of Two Treatments in the Remission of Vasculitis
• Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
• Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
• Abatacept in ANCA Associated Vasculitis
• Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
• Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis
• CellCept in p-ANCA Vasculitis
• WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
• Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
• Intravenous Immunoglobulin After Relapse in Vasculitis
• IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
• RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
• MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
• Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
• Hematopoietic Stem Cell Support in Vasculitis
• Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)
• Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
• Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
• Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
• Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
• Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
• Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
• Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
• Etanercept to Treat Wegener's Granulomatosis
• Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
• Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
• Steroids and Methotrexate to Treat Systemic Vasculitis
• Treatment of Wegener's Granulomatosis With Cyclophosphamide